Where is CellBri located?

CellBri is headquartered in Shenzhen, China.

Is CellBri a funded company?

CellBri is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does CellBri rank among its competitors?

CellBri ranks 89th amongst 78 active competitors, of which 27 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Bio, which secured an undisclosed amount in Aug, 2025.

Who are the top competitors of CellBri?

CellBri's top competitors include 10X Genomics, Mission Bio and LUMICKS. Among them, Mission Bio secured the most recent funding round in August, 2025.

CellBri - 2026 Company Profile, Funding & Competitors

Company Details

Developer of cell and gene therapy production instruments. It offers automated blood cell separation, magnetic bead activation and sorting, electrotransfection, cell expansion, cleaning and concentration, preparation dispensing and other equipments for cell processing, separation, and transfection.

Website: cellbri.com
Email ID: *****@cellbri.com
Phone Number: +86 **********

Key Metrics

Founded Year

2020

Location

Shenzhen, China

Stage

Funding Raised

Investors

Delian Capital

Ranked

89^th among 91 competitors

Similar Companies

10X Genomics & 89 more

View CellBri's full profile

CellBri is a funded company. CellBri has 1 institutional investor.

View details of CellBri's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CellBri include 10X Genomics, Mission Bio and LUMICKS. Here is the list of Top 10 competitors of CellBri, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	10X Genomics 2012, Pleasanton (United States), Public	Developer of single-cell, spatial, and in situ tools for high-resolution biological analysis	$243M	Fidelity Investments, Meritech & 13 others	69/100
2nd	Mission Bio 2014, San Francisco (United States), Series C	Provider of single cell multiomics platform for genotypic and phenotypic analysis	$120M	Cota Capital, Mayfield & 27 others	65/100
3rd	LUMICKS 2014, Amsterdam (Netherlands), Series D	Manufacturer of optical tweezers for single molecule analysis instruments	$93.4M	Farallon Capital Management, Lauxera Capital Partners ... & 11 others	63/100
4th	Atrandi Biosciences 2016, Vilnius (Lithuania), Series A	A life sciences tool company transforming single-cell research with its patented Semi-Permeable Capsule(SPC) technology, enabling high-throughput and multi-step workflows	$31M	Lux Capital, Practica Capital & 4 others	61/100
5th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	59/100
6th	IsoPlexis 2012, New Haven (United States), Acquired	Developer of multiplexed single-cell analysis tools for the diagnostics and life science research	$186M	Northpond Ventures, YEI Innovation Fund & 14 others	54/100
7th	Xcell Biosciences 2012, San Francisco (United States), Series B	Developer of cell culture analysis device for cancer research	$40.9M	Casdin Capital, HBM Genomics & 10 others	52/100
8th	Biolog 1984, Hayward (United States), Series A	Provider of cell-based phenotyping technologies and assays	$33.6M	Broadoak Capital Partners, RCT & 2 others	52/100
9th	LevitasBio 2017, San Francisco (United States), Series C	Developer of single-cell imaging and profiling platform based on magnetic levitation technology	$73.8M	Novalis LifeSciences, Decheng Capital & 1 others	49/100
10th	Rebus Biosystems 2006, Santa Clara (United States), Series B	Developer of an imaging system for the analysis of genes in a single cell	$20M	Illumina Ventures, LabGenomics & 7 others	48/100
89th	CellBri 2020, Shenzhen (China), Funding Raised	Developer of cell and gene therapy production instruments	-	Delian Capital	15/100